Amvuttra
Amvuttra ingredients
| Active ingredient | Strength |
|---|---|
| Vutrisiran Sodium | 25 mg/.5mL |
What Amvuttra is used for
The FDA lists the approved uses on the official label (below). In the EU, vutrisiran is approved as Amvuttra for:
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Amvuttra
- Generic name
- Vutrisiran
- Made by
- Alnylam Pharmaceuticals, Inc.
- Forms
- Injection
- Given
- Subcutaneous
- Drug class
- Small Interfering RNA, Transthyretin-directed RNA Interaction
- FDA approval
- New drug application (NDA) NDA215515
- On the US market since
- 2022
Official information
- Amvuttra prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Vutrisiran)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Amvuttra?
Amvuttra (Vutrisiran) is a specialist medicine made by Alnylam Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Amvuttra?
Amvuttra contains Vutrisiran Sodium (25 mg/.5mL).
Is Amvuttra approved in Europe?
The same active substance is approved in the EU as Amvuttra.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA